Daved Henry Fremont

This inventor holds 13 USPTO granted patents and 10 published patent applications and 3 EPO patents. Top assignees: Washington University, Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.v., Other. Active years: 2009-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daved Henry Fremont. Retrieved from https://idiyas.com/inventor/daved-henry-fremont

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 10)

% Patents Active = 92.3

EPO Patents = 3 (Patent Applications = 7)

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 61(Granted Patents)

Location History:

Saint Louis, MO (US) (2015)
St. Louis, MO (US) (2009 - 2024)

Company Filing History:

11 out of 1,379

Washington University

patents

1 out of 4,921

Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.v.

patents

2 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12448415 - Compositions and methods for inhibition of alphavirus infection (2025-10-21),

2. 11897929 - Compositions and methods for targeted cytokine delivery (2024-02-13),

3. 11834494 - Antibodies to zika virus and methods of use thereof (2023-12-05),

4. 11713342 - Compositions and methods for targeted cytokine delivery (2023-08-01),

5. 11351227 - Chemokine decoy receptors of rodent gammaherpesviruses and uses thereof (2022-06-07),

6. 11248036 - Mutant tumor necrosis factor receptor superfamily (TNFsfR) ligands and methods of making and using same (2022-02-15),

7. 11053293 - Compositions and methods for targeted cytokine delivery (2021-07-06),

8. 10793613 - Compositions and methods for targeted cytokine delivery (2020-10-06),

9. 10550169 - Oligomers for TNF superfamily inhibition, methods of making and using (2020-02-04),

10. 10060924 - Distinguishing flavivirus infection using a recombinant mutant envelope protein (2018-08-28),

11. 9914761 - Oligomers for TNF superfamily inhibition (2018-03-13),

12. 8992937 - Disulfide trap MHC class I molecules and uses therefor (2015-03-31),

13. 7498419 - Crystals and structure of domain III of West Nile Virus envelope protein in association with a Fab fragment of a neutralizing antibody (2009-03-03),

Title: Daved Henry Fremont: Innovator in Immunotherapy

Introduction

Daved Henry Fremont is a notable inventor based in St. Louis, MO (US). He has made significant contributions to the field of immunotherapy, holding a total of 13 patents. His work focuses on developing innovative compositions and methods that enhance treatment options for various viral infections and improve immunotherapy outcomes.

Latest Patents

Among his latest patents is a groundbreaking invention titled "Compositions and methods for inhibition of alphavirus infection." This patent provides compositions and methods for treating arthritogenic alphavirus infections and includes methods for screening potential treatments. Another significant patent is "Compositions and methods for targeted cytokine delivery." This invention encompasses compositions that link cytokines to NKG2D ligands or PD1 ligands, aiming to improve immunotherapy by minimizing associated side effects. Additionally, it includes methods for recruiting cytotoxic lymphocytes to target cells, enhancing the effectiveness of immunotherapy.

Career Highlights

Daved has worked with Washington University, where he has contributed to various research initiatives. His innovative approaches have positioned him as a key figure in the development of new therapeutic strategies.

Collaborations

Daved has collaborated with notable individuals in his field, including Christopher Nelson and Alexander Sasha Krupnick. These partnerships have furthered his research and expanded the impact of his inventions.

Conclusion

Daved Henry Fremont's contributions to immunotherapy through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in treatment options for viral infections and immunotherapy.

Profile summary based on public USPTO records.